Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
Vastesaeger N, Kutzbach AG, Amital H, Pavelka K, Lazaro MA, Moots RJ, Wollenhaupt J, Zerbini CA, Louw I, Combe B, Beaulieu A, Schulze-Koops H, Dasgupta B, Fu B, Huyck S, Weng HH, Govoni M, Durez P. Vastesaeger N, et al. Among authors: weng hh. Rheumatology (Oxford). 2016 Aug;55(8):1466-76. doi: 10.1093/rheumatology/kew179. Epub 2016 Apr 25. Rheumatology (Oxford). 2016. PMID: 27114562 Free PMC article. Clinical Trial.
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.
Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH; GO-MORE Investigators. Combe B, et al. Among authors: weng hh. Ann Rheum Dis. 2014 Aug;73(8):1477-86. doi: 10.1136/annrheumdis-2013-203229. Epub 2013 Jun 5. Ann Rheum Dis. 2014. PMID: 23740226 Free PMC article. Clinical Trial.
Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A, Schulze-Koops H, Durez P, Wolff V, Yao R, Weng HH, Govoni M, Vastesaeger N. Dasgupta B, et al. Among authors: weng hh. Arthritis Care Res (Hoboken). 2014 Dec;66(12):1799-807. doi: 10.1002/acr.22371. Arthritis Care Res (Hoboken). 2014. PMID: 24839031 Free article. Clinical Trial.
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
Weng HH, Ranganath VK, Khanna D, Oh M, Furst DE, Park GS, Elashoff DA, Sharp JT, Gold RH, Peter JB, Paulus HE; Western Consortium of Practicing Rheumatologists. Weng HH, et al. J Rheumatol. 2010 Mar;37(3):550-7. doi: 10.3899/jrheum.090818. Epub 2010 Jan 28. J Rheumatol. 2010. PMID: 20110517 Free PMC article.
A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis.
Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, Berd Y, Bergman G, Curtis S, Tzontcheva A, Huyck S, Weng HH. Sieper J, et al. Among authors: weng hh. Arthritis Rheumatol. 2015 Oct;67(10):2702-12. doi: 10.1002/art.39257. Arthritis Rheumatol. 2015. PMID: 26139307 Free PMC article. Clinical Trial.
SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.
Wobst HJ, Viader A, Muncipinto G, Hollibaugh R, van Kalken D, Burkhart CT, Cantin SM, Bates RM, Regimbald-Dumas Y, Gross L, Antalek MT, Zweig JE, Wu F, Rettenmaier TJ, Labenski MT, Pullen N, Blanchette HS, Henderson JL, Weng HH, Vaughn TA, Brown DG, Throup JP, Barrish JC. Wobst HJ, et al. Among authors: weng hh. JCI Insight. 2024 Nov 8;9(21):e182876. doi: 10.1172/jci.insight.182876. JCI Insight. 2024. PMID: 39513367 Free article. Clinical Trial.
166 results